A Phase 3 Study of 2 Dose Regimens of Telaprevir [VX-950] in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2015
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ADVANCE
- Sponsors Vertex Pharmaceuticals
- 20 May 2015 Results of pooled data from ADVANCE, QUEST 1 and 2 trials comparing efficacy of simeprevir and telaprevir presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 30 Jun 2012 Additional location (United Kingdom) added as reported by European Clinical Trials Database.
- 20 Jul 2011 Additional trial locations added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History